Head-to-head · Cost-Efficiency Index
Boston Medical Group vs Invyncible
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
Boston Medical Group
Cost-first shoppers who want a clinician-run 12-week program and can accept a price quoted as a range rather than a rate.
Visit Boston Medical GroupInvyncible
Cost-first shoppers who want compounded GLP-1 combo programs (with B12/glycine) alongside brand Wegovy/Zepbound on one platform.
Visit InvyncibleThe verdict
Boston Medical Group and Invyncible tie on the Cost-Efficiency Index at 59/100, so neither wins outright on the numbers. For most shoppers we'd start with Boston Medical Group (ranked #269, a hair above #272) — Cost-first shoppers who want a clinician-run 12-week program and can accept a price quoted as a range rather than a rate. But Invyncible is a genuine coin-flip alternative here.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs Boston Medical Group.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | Boston Medical Group | Invyncible |
|---|---|---|
| Cost-Efficiency Index | 59/100 | 59/100 |
| Semaglutide / mo | $199/mo (starting strength, rising with dose, compounded) | $149/mo (0.45 mg dose, compounded with glycine + B12) |
| Tirzepatide / mo | Not disclosed | $180/mo (2.5 mg weekly, 4-week program, compounded) |
| Semaglutide / yr (modeled) | $2,388 | $1,788 |
| Tirzepatide / yr (modeled) | — | $2,160 |
| Coverage | 7 states | 46 states plus DC |
| Oral / sublingual | No | Yes |
| Brand-name access | Compounded only | Yes |
| Rank here | #269 | #272 |
Boston Medical Group
59/100Where the value is
- An established medical group with a defined 12-week program rather than an open-ended subscription
- The price range and the 12-week total are both published, once you reach the costs page
- Semaglutide is prescribed and dispensed under a compounded pathway with clinician oversight
The tradeoffs
- The published rate is a range by dose strength, $199 to $299, so the figure quoted is the floor rather than what a titrated patient pays
- The 12-week program totals $699 including a telemedicine platform fee that is never itemised — about $233/mo all-in, not $199
Invyncible
59/100Where the value is
- Publishes real itemized dollar prices for eight separate combo programs plus two brand options directly on the site, no signup required, with the mg vial size named in every dose option
- Sells FDA-approved brand Wegovy ($1,750/mo) and Zepbound ($1,540/mo) alongside compounded options
- Names all six compounding pharmacies with street addresses and phone numbers and lets the patient choose which one fills the prescription
The tradeoffs
- Every listed price is shown as a discount off a much higher struck-through 'list' price, and the page invites further negotiation — reads as permanent anchor pricing
- The entry figure is the smallest vial: plain compounded semaglutide runs $192.50, $262.50 and $350 across its three vial sizes, and the FAQ confirms cost rises with dose
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.